Meropenem (Merrem)

A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.

Also Known As:

Merrem; 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; Penem; Ronem; SM 7338; SM-7338; SM7338; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-

Networked: 2340 relevant articles (284 outcomes, 452 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nicolau, David P: 45 articles (01/2024 - 05/2003)
2.	Roberts, Jason A: 42 articles (11/2022 - 07/2009)
3.	Lipman, Jeffrey: 33 articles (01/2024 - 04/2009)
4.	Pea, Federico: 21 articles (03/2024 - 07/2011)
5.	Wallis, Steven C: 19 articles (03/2022 - 05/2013)
6.	Kuti, Joseph L: 19 articles (09/2019 - 04/2004)
7.	Paterson, David L: 16 articles (02/2024 - 06/2004)
8.	Viale, Pierluigi: 15 articles (03/2024 - 12/2012)
9.	Zoller, Michael: 14 articles (01/2023 - 04/2015)
10.	Huntington, Jennifer A: 13 articles (09/2023 - 12/2019)

Related Diseases

1.	Infections 01/01/2016 - "Herein we describe the results of dose fractionation and dose-ranging studies carried out using a one-compartment in vitro infection model to determine the exposure measure for CB-618, a novel β-lactamase inhibitor, most predictive of the efficacy when given in combination with meropenem. " 03/01/2016 - "Based on our results, meropenem administered as a extended infusion is the best option to treat infections due to E. " 01/01/2019 - "Meropenem monotherapy using a high dose of 2 g every 8 h (q 8 h) and a 3-h traditional simple prolonged-infusion (TSPI) has proven to be helpful for the treatment of infections due to MNBSs with MICs of 4-8 mg/L but is limited for cases with higher MICs of ≥16 mg/L. " 08/01/2011 - "This is the first report of a meropenem-non-susceptible carbapenamase-positive Klebsiella pneumoniae blood stream infection treated successfully with high-dose, continuous-infusion meropenem. " 08/01/2011 - "High-dose, continuous-infusion meropenem achieved serum drug concentrations above the minimum inhibitory concentration and eradicated the infection. "
2.	Sepsis (Septicemia) 07/01/2021 - "Moreover, the area under the curve and the maximum concentrations in the plasma of meropenem in control rabbits were significantly smaller (P < 0.05), while clearance and distribution volumes were significantly greater (P < 0.05) than in those with sepsis. " 01/01/2020 - "This case reported that a premature infant with CRE bloodstream infection was treated successfully with high-dose meropenem treatment with model-based therapeutic drug monitoring (TDM). " 01/01/2020 - "Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate." 10/12/2023 - "In the murine sepsis model, AtCs exhibited favorable synergistic efficacy with Meropenem, along with acceptable pharmacokinetics and safety profiles. " 01/01/2017 - "coli sepsis, the PPMO improved survival (92%) and reduced systemic bacterial burden when given concomitantly with meropenem. "
3.	Intraabdominal Infections 06/01/2000 - "Meropenem appeared to be slightly more effective against intra-abdominal infections: 95.5% (21/22) versus 76.7% (23/30), respectively. " 09/01/2000 - "Extensive comparative clinical data demonstrate that meropenem can be used effectively as empirical monotherapy in moderate to severe intra-abdominal infections. " 09/01/1997 - "Finally, the authors analyze the literature and the evidence reported regarding the use of meropenem in clinical practice, as a treatment of intraabdominal infections with a clinical response of 91%-100% and bacteriologic efficacy of 84%-95%." 12/01/2012 - "The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections. " 09/01/2000 - "In patients with moderate to severe intra-abdominal infections, empirical monotherapy with meropenem achieved clinical response rates ranging from 91 to 100% in 7 randomised comparative trials. "
4.	Pneumonia (Pneumonitis) 08/01/2016 - "This infant male, whose risk factors included vacuum extraction during delivery and suspected post-natal pneumonia, responded well to a 6-week course of intravenous meropenem with complete resolution of both lesions. " 02/15/2024 - "In the pneumonia model, CF-370 alone decreased bacterial densities in lungs, kidneys and spleen vs. vehicle control, and demonstrated significantly increased efficacy when combined with meropenem (vs either agent alone). " 01/01/2017 - "Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa." 09/28/2023 - "For ventilatorassociated pneumonia (VAP), the consensus for the drug of first choice was agreed as meropenem. " 01/01/2022 - "Therefore, we plan to conduct a multicenter randomized controlled trial (RCT) to compare the efficacy and safety between conventional regimen and model regimen for meropenem in pediatric severe pneumonia. "
5.	Critical Illness (Critically Ill) 04/01/2022 - "The findings of this study suggest that CRP might be helpful in managing meropenem dosing in critically ill patients. " 06/28/2012 - "Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial." 02/01/2024 - "This study investigated predictors of in-hospital mortality in critically ill patients treated with meropenem by pharmacometric multistate modeling. " 01/01/2023 - "This study aimed to investigate the pharmacokinetics and target attainment of meropenem and compare the effect of meropenem dosing regimens in critically ill patients. " 01/01/2023 - "In the present study, population pharmacokinetic (PK) analysis was performed based on meropenem data from a prospective study conducted in 114 critically ill patients with a wide range of renal functions and various disease conditions. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Imipenem
3.	Carbapenems (Carbapenem Antibiotics)
4.	Ceftazidime (Fortum)
5.	Imipenem Drug Combination Cilastatin (Primaxin)
6.	Vancomycin
7.	Amikacin (A.M.K)
8.	Ciprofloxacin (Cipro)
9.	Tazobactam Drug Combination Piperacillin (Zosyn)
10.	Cefepime (Maxipime)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Catheters
4.	Intravenous Administration
5.	Peritoneal Dialysis